Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
Enabling the next generation of human induced pluripotent stem cell derived hematopoietic stem cell-based therapies
FY 2021-22
Summary
Human induced pluripotent stem cells (iPSCs) present a renewable and scalable cell source for patient-specific hematopoietic stem progenitor cells (HSPCs) and blood cell products, which can be used to cure many blood diseases. However, a bottleneck hindering translation of this promising strategy is the efficient production of iHSCs and iHPCs from iPSCs. Small molecule stem cell agonist cocktails (SCACs) promoted cord blood-derived HSPC expansion and demonstrated high levels of in vivo engraftment. However, the effects of SCAC expansion on iPSC-derived iHSPCs and multipotent progenitor cells (iMPPs) is unknown. In this project, we aim to test SCACs to improve iHSPC and iMPP differentiation and expansion. We hypothesize that SCACs will enable an efficient and scalable production of human iHSPCs and iMPPs through the additive and synergistic ex vivo expansion activities of small molecules. In this study, we will use the monolayer differentiation strategy to generate CD34+CD43+ iHSPCs from iPSCs. We will assess the modulating activity of SCACs to identify an optimal formulation to preferentially expand iHSPCs and iMPPs. iHSPC/iMPP cell yields will be assessed by real-time imaging (IncuCyte) and flow cytometry. The potency of expanded iHSPC/iMPPs will be assessed by a colony-forming unit assay and we will determine the transcriptional profile of expanded immune cells using RNASeq. If SCACs significantly benefit the net output of Lin-CD43+CD34+ subpopulations or lymphoid cells in vitro, we will perform in vivo transplant experiments to assess engraftment activity. Identifying a strategy to expand iPSC-derived iHSPC and immune cell derivatives will enable the next generation of accessible, scalable and affordable therapeutic options for patients and HSPC biomanufacturing.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
466660
Name
Wong Casey K
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Enabling the next generation of human induced pluripotent stem cell derived hematopoietic stem cell-based therapies
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Engraftment; Expansion; Hematopoietic Stem Progenitor Cell; Human Induced Pluripotent Stem Cell; Multipotent Progenitor Cell; Small Molecule; Stem Cell Agonist Cocktail; Stemregenin 1; Um171; Valproic Acid
Abstract
Human induced pluripotent stem cells (iPSCs) present a renewable and scalable cell source for patient-specific hematopoietic stem progenitor cells (HSPCs) and blood cell products, which can be used to cure many blood diseases. However, a bottleneck hindering translation of this promising strategy is the efficient production of iHSCs and iHPCs from iPSCs. Small molecule stem cell agonist cocktails (SCACs) promoted cord blood-derived HSPC expansion and demonstrated high levels of in vivo engraftment. However, the effects of SCAC expansion on iPSC-derived iHSPCs and multipotent progenitor cells (iMPPs) is unknown. In this project, we aim to test SCACs to improve iHSPC and iMPP differentiation and expansion. We hypothesize that SCACs will enable an efficient and scalable production of human iHSPCs and iMPPs through the additive and synergistic ex vivo expansion activities of small molecules. In this study, we will use the monolayer differentiation strategy to generate CD34+CD43+ iHSPCs from iPSCs. We will assess the modulating activity of SCACs to identify an optimal formulation to preferentially expand iHSPCs and iMPPs. iHSPC/iMPP cell yields will be assessed by real-time imaging (IncuCyte) and flow cytometry. The potency of expanded iHSPC/iMPPs will be assessed by a colony-forming unit assay and we will determine the transcriptional profile of expanded immune cells using RNASeq. If SCACs significantly benefit the net output of Lin-CD43+CD34+ subpopulations or lymphoid cells in vitro, we will perform in vivo transplant experiments to assess engraftment activity. Identifying a strategy to expand iPSC-derived iHSPC and immune cell derivatives will enable the next generation of accessible, scalable and affordable therapeutic options for patients and HSPC biomanufacturing.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wong, Casey K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~